EARLY ONSET OF ANGIOEDEMA AND URTICARIA IN ADOLESCENTS HAVING CROSS-REACTIVE HYPERSENSITIVITY TO NONSTEROIDAL ANTI-INFLAMMATORY MEDICINES

Aim: Early onset of angioedema and urticaria in adolescents having cross-reactive hypersensitivity to nonsteroidal anti-inflammatory medicines.

Methods: The Taiwan Longitudinal Health Insurance Database was studied. Patients who had suffered from urticaria or sadness previous to trial period have been barred from participation. A number of 6747 teenagers (aged 12 to 19 years) hospitalized for the first-attack urticaria incident among May 2021 and April 2022 have been enrolled as a research group, alongside 21,230 matchings no urticaria enrollees serving as a control group. Every individual has been monitored prospectively for a year to detect bouts of depression. To examine the prevalence of depression between control and study groups, Cox proportional hazards models were employed with modifications for the individuals' locations of residence also sociodemographic data. Curves of depression-free survival have similarly been examined. Lastly, the symptoms of depression have been compared among age ranges.

Results: During the follow-up phase, 66 (0.8%) teenagers having urticaria and 62 (0.4%) non-urticarial control youths developed a second bout of depression. According to the stratification Cox proportional analyses, the crude relative risk of sadness amongst teenagers having urticaria was 1.87 times (96% CI, 1.26 + 2.97) that of control persons without urticaria. Individuals aged 15 to 19 and with the past record of asthma remained extra susceptible to depression (p 0.06 for both). Lastly, urticaria remained found to remain very risky aspect for depressive disorders solitary throughout adolescence, not in individuals aged 14 years (n 14 6746) or 18 to 25 years (n 14 7186).

Conclusion: People who have their first urticaria episode throughout adolescence are more likely to become depressed.

Keywords: Onset of Angioedema, Urticaria in Adolescents, Hypersensitivity, Nonsteroidal Anti-Inflammatory Medicines.